1.	XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML18530, NCT00127933
2.	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XRP6976J_4001, NCT00280098
3.	Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D7913C00046, NCT00536107
4.	Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MC#08-002, IIT 12230, NCT00883675
5.	Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy Phase: Phase IV Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: DOCET_L_04827, NCT01038661
6.	A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen Phase: Phase IV Type: Supportive care Status: Completed Age: 21 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: DOCET_L_04775, U1111-1116-9574, NCT01107756
7.	Phase II/III Randomized Study of Docetaxel With or Without Oblimersen (Bcl-2 Antisense Oligonucleotide; G3139 ) in Patients With Previously Treated Non-Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: GENTA-GN304, NCI-G01-2046, UCLA-0301058, NCT00030641
8.	Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: NBCG10, REK 378-04-03133, NMA 03-07568, NCT00201435
9.	Docetaxel in Head and Neck Cancer Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XRP6976F_2503, NCT00261703
10.	Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients Phase: Phase III, Phase II Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: GEICAM/2006-14, Nº EudraCT 2007-007031-13, NCT00841828
11.	Phase III Randomized Study of Mitoxantrone With or Without Docetaxel as First-Line Chemotherapy for Women With Poor Risk Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 80 and under Sponsor: Other Protocol IDs: GER-AIO-01/92, EU-93011, NCT00002544
12.	Phase III Randomized Study of Docetaxel Versus Paclitaxel in Women With Metastatic or Locally Advanced, Inoperable Adenocarcinoma of the Breast Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AVENTIS-56976-TAX-311, RP-56976-TAX-311, NCI-V95-0680, NCT00002662
13.	Phase III Randomized Study of TXT vs DOX as First-Line Chemotherapy for Locally Advanced and/or Metastatic Soft Tissue Sarcoma (Summary Last Modified 09/95) Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Protocol IDs: EORTC-62941
14.	Phase III Randomized Study of High-Dose vs Low-Dose Docetaxel vs Standard Chemotherapy with Vinorelbine or Ifosfamide for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy (Summary Last Modified 08/97) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MSKCC-95088, RP-56976-TAX-320, NCI-V96-0830
15.	Phase III Randomized Study of Standard Chemotherapy with Paclitaxel/Cisplatin vs Gemcitabine/Cisplatin vs Docetaxel/Cisplatin vs Paclitaxel/Carboplatin in Metastatic non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: E-1594, E1594
16.	Phase III Randomized Study of Surgery With or Without Preoperative Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: Other Protocol IDs: MRC-LU22, EORTC-08012, EU-97016, ISRCTN25582437, NCT00003159
17.	Phase III Randomized Study of Adjuvant Fluorouracil, Epirubicin, and Cyclophosphamide with or without Docetaxel in Women with Nonmetastatic Breast Cancer with Lymph Node Invasion Phase: Phase III Type: Treatment Status: Closed Age: 18 to 69 Sponsor: Protocol IDs: FRE-FNCLCC-PACS-01, EU-98044
18.	Phase III Randomized Study of Doxorubicin in Combination With Either Docetaxel or Cyclophosphamide in Women With Potentially Operable Locally Advanced or Inflammatory Breast Cancer (Summary Last Modified 06/2002) Phase: Phase III Type: Treatment Status: Closed Age: 18 to 60 Sponsor: Protocol IDs: SCTN-BR9809, EU-98053, NCT00003679
19.	Phase III Randomized Study of Docetaxel Plus Cisplatin or Docetaxel Plus Carboplatin versus Vinorelbine Plus Cisplatin in Chemotherapy-Naive Patients with Unresectable, Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RP-56976-TAX-326, RP-56976-V-326
20.	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Other Protocol IDs: CDR0000067057, EORTC-24971, RP-56976-V-323, NCT00003888
21.	Phase III Randomized Study of SC-70935 Following Docetaxel, Doxorubicin, and Cyclophosphamide in Patients with Recurrent or Newly Diagnosed Breast Cancer (Summary Last Modified 01/2000) Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SC-NN5-98-02-010
22.	Phase III Randomized Study of Paclitaxel and Carboplatin Versus Docetaxel and Carboplatin in Chemotherapy Naive Patients With Stage IC-IV Ovarian Epithelial Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: CRC-BOC-SCOTROC, EU-99010, NCT00003998
23.	Phase III Randomized Study of Docetaxel and Estramustine Versus Mitoxantrone and Prednisone in Patients With Hormone-Refractory, Metastatic Adenocarcinoma of the Prostate Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S9916, CLB-99808, NCCTG-S9916, NCT00004001, S9916
24.	Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 to 75 Sponsor: Other Protocol IDs: SAKK 43/99, SWS-SAKK-43/99, EU-99042, NCT00005060
25.	Docetaxel in Treating Patients With Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: ID99-242, P30CA016672, MDA-ID-99242, AVENTIS-MDA-ID-99242, NCI-1691, CDR0000068408, 1691, NCT00008411